Oral bisphosphonate therapy and osteonecrosis of the jaw: What to tell the concerned patient

Sreenivas Koka, Bart Clarke, Shreyasee Amin, Morie Gertz, Salvatore L. Ruggiero

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is encountered predominantly in cancer populations being treated with high-dose intravenous bisphosphonates for skeletal complications such as bone metastases and secondary fracture risk. A minority of BONJ lesions have been observed in patients receiving oral bisphosphonates for management of osteoporosis or osteopenia. In this paper, the current knowledge pertaining to the incidence, definition, and signs and symptoms of BONJ is presented, followed by a discussion of the incidence and consequences of osteoporotic skeletal fracture and the use of oral bisphosphonates to mitigate fracture. The risk of BONJ appears to be very small in patients taking oral bisphosphonates. In addition, the consequences of osteoporotic fracture likely have significantly greater mortality and morbidity than BONJ. Within this context, management concepts and guidelines are presented to help the dental clinician allay concerns about BONJ expressed by patients receiving oral bisphosphonate therapy.

Original languageEnglish (US)
Pages (from-to)115-122
Number of pages8
JournalInternational Journal of Prosthodontics
Volume20
Issue number2
StatePublished - Mar 2007

Fingerprint

Bisphosphonate-Associated Osteonecrosis of the Jaw
Jaw
Diphosphonates
Osteoporotic Fractures
Therapeutics
Metabolic Bone Diseases
Incidence
Osteoporosis
Signs and Symptoms
Tooth
Guidelines
Neoplasm Metastasis
Morbidity
Bone and Bones
Mortality
Population

ASJC Scopus subject areas

  • Dentistry(all)

Cite this

Oral bisphosphonate therapy and osteonecrosis of the jaw : What to tell the concerned patient. / Koka, Sreenivas; Clarke, Bart; Amin, Shreyasee; Gertz, Morie; Ruggiero, Salvatore L.

In: International Journal of Prosthodontics, Vol. 20, No. 2, 03.2007, p. 115-122.

Research output: Contribution to journalArticle

@article{f247f2fdb8f048459d02ada682f6fc06,
title = "Oral bisphosphonate therapy and osteonecrosis of the jaw: What to tell the concerned patient",
abstract = "Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is encountered predominantly in cancer populations being treated with high-dose intravenous bisphosphonates for skeletal complications such as bone metastases and secondary fracture risk. A minority of BONJ lesions have been observed in patients receiving oral bisphosphonates for management of osteoporosis or osteopenia. In this paper, the current knowledge pertaining to the incidence, definition, and signs and symptoms of BONJ is presented, followed by a discussion of the incidence and consequences of osteoporotic skeletal fracture and the use of oral bisphosphonates to mitigate fracture. The risk of BONJ appears to be very small in patients taking oral bisphosphonates. In addition, the consequences of osteoporotic fracture likely have significantly greater mortality and morbidity than BONJ. Within this context, management concepts and guidelines are presented to help the dental clinician allay concerns about BONJ expressed by patients receiving oral bisphosphonate therapy.",
author = "Sreenivas Koka and Bart Clarke and Shreyasee Amin and Morie Gertz and Ruggiero, {Salvatore L.}",
year = "2007",
month = "3",
language = "English (US)",
volume = "20",
pages = "115--122",
journal = "International Journal of Prosthodontics",
issn = "0893-2174",
publisher = "Quintessence Publishing Company",
number = "2",

}

TY - JOUR

T1 - Oral bisphosphonate therapy and osteonecrosis of the jaw

T2 - What to tell the concerned patient

AU - Koka, Sreenivas

AU - Clarke, Bart

AU - Amin, Shreyasee

AU - Gertz, Morie

AU - Ruggiero, Salvatore L.

PY - 2007/3

Y1 - 2007/3

N2 - Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is encountered predominantly in cancer populations being treated with high-dose intravenous bisphosphonates for skeletal complications such as bone metastases and secondary fracture risk. A minority of BONJ lesions have been observed in patients receiving oral bisphosphonates for management of osteoporosis or osteopenia. In this paper, the current knowledge pertaining to the incidence, definition, and signs and symptoms of BONJ is presented, followed by a discussion of the incidence and consequences of osteoporotic skeletal fracture and the use of oral bisphosphonates to mitigate fracture. The risk of BONJ appears to be very small in patients taking oral bisphosphonates. In addition, the consequences of osteoporotic fracture likely have significantly greater mortality and morbidity than BONJ. Within this context, management concepts and guidelines are presented to help the dental clinician allay concerns about BONJ expressed by patients receiving oral bisphosphonate therapy.

AB - Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is encountered predominantly in cancer populations being treated with high-dose intravenous bisphosphonates for skeletal complications such as bone metastases and secondary fracture risk. A minority of BONJ lesions have been observed in patients receiving oral bisphosphonates for management of osteoporosis or osteopenia. In this paper, the current knowledge pertaining to the incidence, definition, and signs and symptoms of BONJ is presented, followed by a discussion of the incidence and consequences of osteoporotic skeletal fracture and the use of oral bisphosphonates to mitigate fracture. The risk of BONJ appears to be very small in patients taking oral bisphosphonates. In addition, the consequences of osteoporotic fracture likely have significantly greater mortality and morbidity than BONJ. Within this context, management concepts and guidelines are presented to help the dental clinician allay concerns about BONJ expressed by patients receiving oral bisphosphonate therapy.

UR - http://www.scopus.com/inward/record.url?scp=34047235731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34047235731&partnerID=8YFLogxK

M3 - Article

C2 - 17455429

AN - SCOPUS:34047235731

VL - 20

SP - 115

EP - 122

JO - International Journal of Prosthodontics

JF - International Journal of Prosthodontics

SN - 0893-2174

IS - 2

ER -